Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 TauRx Expands Alzheimer's Programs | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

TauRx Expands Alzheimer’s Programs

Adds 35 research centers in U.S. for LMTX studies

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

TauRx Therapeutics has expanded its international clinical program by adding 35 new research centers across the U.S. The addition of these clinical research centers means that more patients suffering from mild or moderate Alzheimer’s, and their caregivers, will have an opportunity to see if they qualify for participation in TauRx’s Alzheimer’s clinical trials, according to the company.

The company’s lead treatment, second generation tau aggregation inhibitor LMTX, is being evaluated in Phase III clinical trials for Alzheimer’s. LMTX targets the tangles of tau protein that develop in the brain.

TauRx’s Phase III studies are designed to evaluate the effects of LMTX on slowing and/or halting the progression of Alzheimer’s disease. The expansion of study centers in the U.S. includes areas such as Bennington, VT; Farmington Hills, MI; Waukesha, WI; and Creve Coeur, MO.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics